Advanced search
Publication Cover
Expert Opinion on Drug Safety Latest Articles
Submit an article Journal homepage
53
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Comparative analysis of adverse events among intravesical drugs in bladder cancer: a real-world study on FAERS database

Yun PengDepartment of Urology, Peking University People’s Hospital, Beijing, ChinaView further author information
,
Yuxuan SongDepartment of Urology, Peking University People’s Hospital, Beijing, ChinaView further author information
,
Yiqing DuDepartment of Urology, Peking University People’s Hospital, Beijing, ChinaCorrespondence[email protected]
View further author information
,
Caipeng QinDepartment of Urology, Peking University People’s Hospital, Beijing, ChinaCorrespondence[email protected]
View further author information
&
Tao XuDepartment of Urology, Peking University People’s Hospital, Beijing, ChinaCorrespondence[email protected]
View further author information
Received 29 Apr 2024, Accepted 20 Jun 2024, Published online: 04 Jul 2024

References

  • Babjuk M, Burger M, Capoun O, et al. European Association of urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75–94. doi: 10.1016/j.eururo.2021.08.010
  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
  • Pazir Y, Esmeray A, Caglar U, et al. Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis. Int Urol Nephrol. 2023;56(3):957–963. doi: 10.1007/s11255-023-03849-x
  • Thomsen JA, Nielsen Dominiak H, Lindgren MS, et al. Adverse events of hyperthermic intravesical chemotherapy for non-muscle invasive bladder cancer patients. Scand J Urol. 2021;55(4):281–286. doi: 10.1080/21681805.2021.1938664
  • The newly available FAERS public dashboard: implications for health care professionals – PMC [Internet]. [cited 2023 Nov 7]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431724/
  • Brown EG, Wood L, Wood S. The Medical Dictionary for Regulatory Activities (MedDRA). Drug-Safety. 1999;20(2):109–117. doi: 10.2165/00002018-199920020-00002
  • Khaleel MA, Khan AH, Ghadzi SMS, et al. A standardized dataset of a spontaneous adverse event reporting system. Healthcare (Basel). 2022;10(3):420. doi: 10.3390/healthcare10030420
  • Olaleye D. Real-world evidence and population health analytics: intersection and application SAS Global Forum Proceedings 2019 2019.04.28-2019.05.01 2019 https://support.sas.com/resources/papers/proceedings19/3361-2019.pdf.
  • Witjes JA, Palou J, Soloway M, et al. Clinical practice recommendations for the prevention and management of intravesical therapy–associated adverse events. Eur Urol Suppl. 2008;7(10):667–674. doi: 10.1016/j.eursup.2008.08.001
  • Thrasher JB, Crawford ED. Complications of intravesical chemotherapy. Urologic Clini North Am. 1992;19(3):529–539. doi: 10.1016/S0094-0143(21)00419-5
  • Decaestecker K, Oosterlinck W. Managing the adverse events of intravesical Bacillus Calmette–Guérin therapy. RRU. 2015;7:157–163. doi: 10.2147/RRU.S63448
  • Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol. 2006;175(6):2004–2010. doi: 10.1016/S0022-5347(06)00264-3
  • Matsuoka Y, Taoka R, Kohashiguchi K, et al. Efficacy and toxicity of intravesical Bacillus Calmette-Guérin therapy in elderly patients with non-muscle-invasive bladder cancer. Curr Urol. 2021;15(1):16. doi: 10.1097/CU9.0000000000000011
  • Krege S, Giani G, Meyer R, et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus Bacillus Calmette-Guerin. J Urol. 1996;156(3):962–966. doi: 10.1016/S0022-5347(01)65673-8
  • Rischmann P, Desgrandchamps F, Malavaud B, et al. BCG intravesical instillations: recommendations for side-effects management. Eur Urol. 2000;37(Suppl. 1):33–36. doi: 10.1159/000052381
  • Pommier JD, Ben Lasfar N, Van Grunderbeeck N, et al. Complications following intravesical Bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients. Infect Dis (Lond). 2015;47(10):725–731. doi: 10.3109/23744235.2015.1055794
  • Garyfallou GT. Mycobacterial sepsis following intravesical instillation of Bacillus Calmette–Guérin. Acad Emerg Med. 1996;3(2):157–160. doi: 10.1111/j.1553-2712.1996.tb03405.x
  • Naudžiūnas A, Juškaitė R, Žiaugrytė I, et al. Tuberculosis complications after BCG treatment for urinary bladder cancer. Medicina (Kaunas). 2012;48(11):82–565. doi: 10.3390/medicina48110082
  • Taniguchi Y, Nishikawa H, Kimata T, et al. Reactive arthritis after intravesical Bacillus Calmette-Guérin therapy. JCR: J Clinic Rheumatol. 2022;28(2):e583. doi: 10.1097/RHU.0000000000001768
  • Ben Abdelghani K, Fazaa A, Souabni L, et al. Reactive arthritis induced by intravesical BCG therapy for bladder cancer. BMJ Case Rep. 2014;2014:bcr2013202741. doi: 10.1136/bcr-2013-202741
  • Barza Michael J, Blum Jonathan H, Graeme-Cook Fiona M, et al. Case 29-1998. N Engl J Med. 1998;339(12):831–837. doi: 10.1056/NEJM199809173391209
  • Elkabani M, Greene JN, Vincent AL, et al. Disseminated mycobacterium bovis after intravesicular Bacillus Calmette-Gu rin treatments for bladder cancer. Cancer Control. 2000;7(5):476–481. doi: 10.1177/107327480000700512
  • Wolf YG, Wolf DG, Higginbottom PA, et al. Infection of a ruptured aortic aneurysm and an aortic graft with Bacille Calmette-Guérin after intravesical administration for bladder cancer. J Vascular Surg. 1995;22(1):80–84. doi: 10.1016/s0741-5214(95)70092-7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.